OCT 19, 2019 8:59 AM PDT

An alternative for immunotherapy-resistant cancer patients

A twist to traditional immunotherapies could help cancer patients’ immune systems better detect cancer cells, making this new system capable of targeting tumors that more conventional immunotherapies might miss. The research comes from scientists at Yale and was published recently in a study in Nature Immunology.

While immunotherapies have greatly broadened treatment options for many cancer patients by enabling their immune systems to fight cancer on their own, immunotherapy also has its own downfalls. Immunotherapy doesn’t work for all cancers or all individual cancer patients, and in fact, a common form of immunotherapy called checkpoint inhibitors are only effective in about one-third of patients. This is why continued investigation around the human immune system and its connection to cancer is crucial.

The researchers from Yale have created a new system that combines viral gene therapy and CRISPR gene-editing technology. "This is an entirely new form of immunotherapy," said senior author Sidi Chen, who is an assistant professor of genetics. The system is called Multiplexed Activation of Endogenous Genes as Immunotherapy (MAEGI).

MAEGI works like a metal-detector for cancer cells, identifying their location and later tagging them for immune destruction. By doing so, the system is able to convert cold tumors to hot tumors (cold, meaning without immune cells, and hot meaning with immune cells). Additionally, explains Chen, "Once those cells are identified, the immune system immediately recognizes them if they show up in the future.” That allows for earlier future detection.

MAEGI offers hope for patients who do not respond to immunotherapies. Photo: Pixabay

The system was proven to work in mice with melanoma, triple-negative breast and pancreatic tumors. It was capable of either reducing or completely eradicating the tumors, no matter how close or far they were from the primary tumor.

The researchers hope that MAEGI will offer an alternative treatment option for those patients who are resistant to other immunotherapies. The team will be continuing their research to prepare for human clinical trials.

Sources: Yale, Science Daily

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
JUN 26, 2021
Cancer
Immunotherapy Drug Shows Promise for Obese Patients with Breast Cancer
JUN 26, 2021
Immunotherapy Drug Shows Promise for Obese Patients with Breast Cancer
Research shows that obese patients with cancers including ovarian and melanoma may respond better to a certain kind of i ...
JUL 23, 2021
Cancer
Repurposed Antibiotics Show Promise Against Skin Cancer
JUL 23, 2021
Repurposed Antibiotics Show Promise Against Skin Cancer
In experiments with mice, researchers from the Netherlands have found that some antibiotics may be effective in tre ...
AUG 19, 2021
Cancer
Vitamin D Reduces Risk of Early-Onset Colorectal Cancer
AUG 19, 2021
Vitamin D Reduces Risk of Early-Onset Colorectal Cancer
Colorectal cancer (CRC) is the third most diagnosed type of cancer in both men and women in the United States and CRC in ...
AUG 30, 2021
Cancer
A Hot Approach to CAR T Cells
AUG 30, 2021
A Hot Approach to CAR T Cells
Immunotherapy, a type of treatment that targets a patient’s immune system to enhance the natural ability to attack ...
OCT 10, 2021
Cell & Molecular Biology
DNA Can Reveal Treatments for Lung Cancer in 'Never-Smoked' Patients
OCT 10, 2021
DNA Can Reveal Treatments for Lung Cancer in 'Never-Smoked' Patients
There is a well-known causal connection between smoking and lung cancer, and most research on lung cancer has been focus ...
OCT 12, 2021
Immunology
Cancer Drug Helps Alzheimer's Mice Remember
OCT 12, 2021
Cancer Drug Helps Alzheimer's Mice Remember
What if a drug—specifically developed to treat one disease—had the potential to address other non-related co ...
Loading Comments...